These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33350439)

  • 21. Pharmacoepidemiology I: a review of pharmacoepidemiologic study designs.
    Etminan M; Samii A
    Pharmacotherapy; 2004 Aug; 24(8):964-9. PubMed ID: 15338844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Invited commentary: The virtual epidemiologist—promise and peril.
    Diez Roux AV
    Am J Epidemiol; 2015 Jan; 181(2):100-2. PubMed ID: 25480822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Invited commentary: G-computation--lost in translation?
    Vansteelandt S; Keiding N
    Am J Epidemiol; 2011 Apr; 173(7):739-42. PubMed ID: 21415028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Revisiting the washout period in the incident user study design: why 6-12 months may not be sufficient.
    Roberts AW; Dusetzina SB; Farley JF
    J Comp Eff Res; 2015 Jan; 4(1):27-35. PubMed ID: 25565067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Re-evaluating Safety and Effectiveness of Dabigatran Versus Warfarin in a Nationwide Data Environment: A Prevalent New-User Design Study.
    Lin HD; Lai CL; Dong YH; Tu YK; Chan KA; Suissa S
    Drugs Real World Outcomes; 2019 Sep; 6(3):93-104. PubMed ID: 31240630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regarding: Webster-Clark M., et al. Alternative analytic and matching approaches for the prevalent new-user design: a simulation study. Pharmacoepidemiol Drug Saf, 31, pp. 796-803; 2022.
    Dell'Aniello S; Renoux C; Suissa S
    Pharmacoepidemiol Drug Saf; 2022 Dec; 31(12):1317-1318. PubMed ID: 36125081
    [No Abstract]   [Full Text] [Related]  

  • 27. Reporting and variability of constructing medication treatment episodes in pharmacoepidemiology studies: A methodologic systematic review using the case study of DPP-4 inhibitors and cardiovascular outcomes.
    Weisman A; King LK; Mamdani M
    Pharmacoepidemiol Drug Saf; 2020 Aug; 29(8):939-950. PubMed ID: 32662222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Invited Commentary: Causal Inference Across Space and Time-Quixotic Quest, Worthy Goal, or Both?
    Edwards JK; Lesko CR; Keil AP
    Am J Epidemiol; 2017 Jul; 186(2):143-145. PubMed ID: 28679174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Engaging stakeholders in pharmacoepidemiology research: Current state and recommendations.
    Camelo Castillo W; Heath N; Kim J; Yang K; Ritchey ME; dosReis S; Santanello N; West SL
    Pharmacoepidemiol Drug Saf; 2019 Jun; 28(6):766-776. PubMed ID: 31050092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methods in pharmacoepidemiology.
    Sommet A; Pariente A
    Therapie; 2019 Apr; 74(2):187-197. PubMed ID: 30819408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Case-crossover study design in pharmacoepidemiology: systematic review and recommendations.
    Consiglio GP; Burden AM; Maclure M; McCarthy L; Cadarette SM
    Pharmacoepidemiol Drug Saf; 2013 Nov; 22(11):1146-53. PubMed ID: 24030723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Invited Commentary: Conducting and Emulating Trials to Study Effects of Social Interventions.
    Rojas-Saunero LP; Labrecque JA; Swanson SA
    Am J Epidemiol; 2022 Jul; 191(8):1453-1456. PubMed ID: 35445692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Bias and confounding: pharmacoepidemiological study using administrative database].
    Nojiri S
    Yakugaku Zasshi; 2015; 135(6):793-808. PubMed ID: 26028416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhancing the Effectiveness of Consumer-Focused Health Information Technology Systems Through eHealth Literacy: A Framework for Understanding Users' Needs.
    Kayser L; Kushniruk A; Osborne RH; Norgaard O; Turner P
    JMIR Hum Factors; 2015 May; 2(1):e9. PubMed ID: 27025228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacoepidemiology II: the nested case-control study--a novel approach in pharmacoepidemiologic research.
    Etminan M
    Pharmacotherapy; 2004 Sep; 24(9):1105-9. PubMed ID: 15460170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Applying Machine Learning in Distributed Data Networks for Pharmacoepidemiologic and Pharmacovigilance Studies: Opportunities, Challenges, and Considerations.
    Wong J; Prieto-Alhambra D; Rijnbeek PR; Desai RJ; Reps JM; Toh S
    Drug Saf; 2022 May; 45(5):493-510. PubMed ID: 35579813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Research Techniques Made Simple: Pharmacoepidemiology Research Methods in Dermatology.
    Noe MH; Gelfand JM
    J Invest Dermatol; 2018 Feb; 138(2):e13-e18. PubMed ID: 29389330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of self-controlled designs in pharmacoepidemiology.
    Hallas J; Pottegård A
    J Intern Med; 2014 Jun; 275(6):581-9. PubMed ID: 24635348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of prevalent statin use among older adults identified as statin initiators based on Medicare claims data.
    Young JC; Stürmer T; Lund JL; Funk MJ
    Pharmacoepidemiol Drug Saf; 2016 Jul; 25(7):836-43. PubMed ID: 26991151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extreme restriction design as a method for reducing confounding by indication in pharmacoepidemiologic research.
    Secrest MH; Platt RW; Dormuth CR; Chateau D; Targownik L; Nie R; Doyle CM; Dell'Aniello S; Filion KB
    Pharmacoepidemiol Drug Saf; 2020 Jan; 29 Suppl 1():26-34. PubMed ID: 30628152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.